3 Side Effects & Costs: Gastrointestinal side effects like nausea are common with both drugs, especially during dose escalation
Abstract Insulin-like growth factor-1 (IGF-1) is a pleiotropic protein hormone and has become an attractive therapeutic target because of its multiple roles in various physiological processes, including growth, development, and metabolism
Meaningful fat loss occurs over 12-16 weeks, with weight-loss rates varying by individual metabolism and lifestyle factors
Altogether, muscle loss during GLP1RAs therapy is multifactorial, involving reduced protein intake and negative energy balance, hormonal adaptations, impaired mTOR signaling and protein synthesis, increased proteolysis and potential mitochondrial adaptations, and age, frailty, and physical inactivity as modifiers (Fig
Approximate dose conversion chart The semaglutide to tirzepatide conversion chart provides a more detailed breakdown of these equivalencies